Vivani Medical
Gesloten
1.22 5.17
Overzicht
Wijziging aandelenprijs
24u
Min
1.17
Max
1.24
Inkomsten | -147K -6.8M |
|---|---|
Werknemers | 42 |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +212.5% upside |
Volgende Winsten | 11 aug 2026 |
|---|
Marktkapitalisatie | 4.7M 81M |
|---|---|
Vorige openingsprijs | -3.95 |
Vorige sluitingsprijs | 1.22 |
Vivani Medical Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Vivani Medical Prognose
Koersdoel
By TipRanks
212.5% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 3.75 USD 212.5%
Hoogste 4 USD
Laagste 3.5 USD
Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.
Financieel
Verkoop- en administratiekosten
Winst voor belastingen
Verkoop
Operationele winst
$
Over Vivani Medical
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
